AACR
The firm shared performance study results at a recent meeting and said it has begun processing samples for its first major pharma customer.
At the AACR annual meeting, both companies shared new data on their technologies' performance in detecting early and late-stage cancers.
C2i Genomics Lays Groundwork for Global Launch of Whole-Genome Minimal Residual Disease Test
Premium
With EU lab partnerships and a newly announced CE mark, the company is poised for the first clinical implementations of its solid tumor residual disease test.
The company previewed results from studies slated for presentation next month on both its newly launched MRD assay and soon-to-be launched cancer screening test.
The firm will commercialize its Primary Immune Response assay as a laboratory-developed test to help guide immunotherapy decisions in lung cancer patients.